A-Alpha Bio, a biotechnology company, announced a $20M Series A funding led by Madrona Venture Group. Other participants include Perceptive Advisors' Perceptive Xontogeny Venture Fund (PXV Fund) and Lux Capital.

A-Alpha Bio leverages synthetic biology to quantitatively measure millions of protein-protein interactions and machine learning to generate high-resolution models of protein binding and interaction networks.